Telix Pharmaceuticals 주식 주식분석 | 주식가격 | 뉴스 | TLX.AX | AU000000TLX2 | A2H7JK

날짜	Telix Pharmaceuticals 주식 가격
	22.56 undefined
	22.20 undefined
	23.02 undefined
	23.03 undefined
	22.73 undefined
	22.92 undefined
	22.98 undefined
	23.00 undefined
	23.47 undefined
	23.39 undefined
	23.04 undefined
	22.83 undefined
	22.82 undefined
	22.34 undefined
	22.17 undefined
	21.44 undefined
	20.92 undefined
	21.06 undefined
	20.67 undefined
	21.39 undefined

날짜	Telix Pharmaceuticals 매출	Telix Pharmaceuticals EBIT	Telix Pharmaceuticals 이익
2028e	1.6 조. undefined	474.44 백만 undefined	0 undefined
2027e	1.28 조. undefined	315.14 백만 undefined	0 undefined
2026e	1.34 조. undefined	323.26 백만 undefined	194.77 백만 undefined
2025e	1.02 조. undefined	150.68 백만 undefined	82.89 백만 undefined
2024e	778.13 백만 undefined	97.72 백만 undefined	60.54 백만 undefined
2023	502.55 백만 undefined	17.61 백만 undefined	5.21 백만 undefined
2022	160.1 백만 undefined	-90.81 백만 undefined	-104.08 백만 undefined
2021	7.6 백만 undefined	-76.95 백만 undefined	-80.51 백만 undefined
2020	5.21 백만 undefined	-35.6 백만 undefined	-44.89 백만 undefined
2019	3.49 백만 undefined	-28.36 백만 undefined	-27.87 백만 undefined
2018	195,140 undefined	-17.51 백만 undefined	-13.83 백만 undefined
2017	0 undefined	-6.16 백만 undefined	-6.38 백만 undefined

	매출	EBIT	이익
2017	0 AUD	-6.16 백만 AUD	-6.38 백만 AUD
2018	195,140 AUD	-17.51 백만 AUD	-13.83 백만 AUD
2019	3.49 백만 AUD	-28.36 백만 AUD	-27.87 백만 AUD
2020	5.21 백만 AUD	-35.6 백만 AUD	-44.89 백만 AUD
2021	7.6 백만 AUD	-76.95 백만 AUD	-80.51 백만 AUD
2022	160.1 백만 AUD	-90.81 백만 AUD	-104.08 백만 AUD
2023	502.55 백만 AUD	17.61 백만 AUD	5.21 백만 AUD
2024e	778.13 백만 AUD	97.72 백만 AUD	60.54 백만 AUD
2025e	1.02 조. AUD	150.68 백만 AUD	82.89 백만 AUD
2026e	1.34 조. AUD	323.26 백만 AUD	194.77 백만 AUD
2027e	1.28 조. AUD	315.14 백만 AUD	0 AUD
2028e	1.6 조. AUD	474.44 백만 AUD	0 AUD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e
0	0	0	0.01	0.01	0.16	0.5	0.78	1.02	1.34	1.28	1.6
-	-	-	66.67	40.00	2,185.71	213.75	54.98	30.59	31.89	-4.18	24.92
-	-	10,466.67	60.00	71.43	58.75	62.55	40.36	30.91	23.43	24.45	19.58
0	0	0	3	5	94	314	0	0	0	0	0
-6	-13	-27	-44	-80	-104	5	60	82	194	0	0
-	116.67	107.69	62.96	81.82	30.00	-104.81	1,100.00	36.67	136.59	-	-
127.99	202.12	233.44	257.27	282.21	310.64	323.71	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

48.76	25.77	44.6	77.95	22.04	116.33	123.24
0	0	0.75	0.16	0.73	39.35	64.78
0	0	12.26	14.03	20.12	6.57	7.66
0	0.64	0.54	0.63	3.45	8.48	17.31
0.45	1.01	0.53	0.86	1.21	2.51	31.95
49.21	27.42	58.68	93.63	47.54	173.23	244.93
0.01	0.23	1.9	4.82	6.33	18.84	30.49
0	0	0	0	0	0	12.26
0	1.17	0.08	0.18	0.21	0.33	0.59
1.51	36.31	37.72	54.97	51.63	53.47	104.82
0	3.14	4.22	4.22	4.1	5.52	4.85
0.04	0	0	0	0	3.97	20.45
1.55	40.85	43.93	64.19	62.27	82.12	173.45
50.75	68.27	102.61	157.82	109.81	255.35	418.38

55.56	72.05	115.94	167.06	170.84	370.97	446.27
0	0	0	0	0	0	0
-6.27	-19.2	-45.8	-88.34	-167.53	-290.4	-291.05
-0.02	53.86	-62	299	-1,153	-562	-5,414
0	0	0	0	0	0	-0.9
49.29	52.9	70.08	79.02	2.16	80.01	148.91
0.28	3.25	6.96	5.81	11.88	16.81	32.84
0.25	0.48	0.45	0.48	11.49	31.8	55.01
0.59	3.38	2.72	12.9	13.98	36.31	75.66
345.43	0	0	0	0	0	0
0	1.13	0.49	0.77	0.63	0.64	1.56
1.47	8.24	10.63	19.96	37.98	85.56	165.06
0	0.6	1.64	1.44	1.91	9.81	15.89
0.33	4.37	3.17	0	0	0	0
0	10.59	17.09	57.41	67.77	79.99	76.1
0.33	15.56	21.9	58.85	69.67	89.79	91.98
1.8	23.8	32.53	78.8	107.66	175.35	257.05
51.09	76.71	102.61	157.82	109.81	255.35	405.96

2017	2018	2019	2020	2021	2022	2023
0	0	0	0	0	-104	0
0	0	0	0	0	5	0
0	0	0	0	0	0	0
0	1	9	11	12	18	-14
0	0	0	0	0	35	0
0	0	0	0	0	0	0
0	0	0	0	0	-2	-10
-6	-20	-23	1	-59	-63	23
0	0	0	0	-1	-13	-10
0	-2	0	-1	-2	-16	-25
0	-2	0	0	-1	-3	-14
0	0	0	0	0	0	0
0	0	-1	0	0	1	3
58	0	45	35	3	181	6
54	0	42	34	2	174	10
-2.00	-	-1.00	-	-	-7.00	-
0	0	0	0	0	0	0
42	-45	-13	24	-127	13	56
-6.04	-20.75	-23.8	1.64	-60.67	-77.83	13.09
0	0	0	0	0	0	0

Telix Pharmaceuticals 브루토마진	Telix Pharmaceuticals 이익 마진	Telix Pharmaceuticals EBIT-마진	Telix Pharmaceuticals 이익 마진
2028e	62.56 %	29.58 %	0 %
2027e	62.56 %	24.54 %	0 %
2026e	62.56 %	24.12 %	14.54 %
2025e	62.56 %	14.83 %	8.16 %
2024e	62.56 %	12.56 %	7.78 %
2023	62.56 %	3.5 %	1.04 %
2022	59.29 %	-56.72 %	-65.01 %
2021	66.46 %	-1,012.97 %	-1,059.9 %
2020	61.17 %	-682.89 %	-861.06 %
2019	27.03 %	-813.74 %	-799.63 %
2018	62.56 %	-8,970.5 %	-7,087.13 %
2017	62.56 %	0 %	0 %

	브루토마진	EBIT-마진	이익 마진
2017	62.56 %	0 %	0 %
2018	62.56 %	-8,970.5 %	-7,087.13 %
2019	27.03 %	-813.74 %	-799.63 %
2020	61.17 %	-682.89 %	-861.06 %
2021	66.46 %	-1,012.97 %	-1,059.9 %
2022	59.29 %	-56.72 %	-65.01 %
2023	62.56 %	3.5 %	1.04 %
2024e	62.56 %	12.56 %	7.78 %
2025e	62.56 %	14.83 %	8.16 %
2026e	62.56 %	24.12 %	14.54 %
2027e	62.56 %	24.54 %	0 %
2028e	62.56 %	29.58 %	0 %

날짜	Telix Pharmaceuticals 주당 매출	Telix Pharmaceuticals EBIT 당 주식	Telix Pharmaceuticals 주당 이익
2028e	4.79 undefined	0 undefined	0 undefined
2027e	3.84 undefined	0 undefined	0 undefined
2026e	4 undefined	0 undefined	0.58 undefined
2025e	3.04 undefined	0 undefined	0.25 undefined
2024e	2.32 undefined	0 undefined	0.18 undefined
2023	1.55 undefined	0.05 undefined	0.02 undefined
2022	0.52 undefined	-0.29 undefined	-0.34 undefined
2021	0.03 undefined	-0.27 undefined	-0.29 undefined
2020	0.02 undefined	-0.14 undefined	-0.17 undefined
2019	0.01 undefined	-0.12 undefined	-0.12 undefined
2018	0 undefined	-0.09 undefined	-0.07 undefined
2017	0 undefined	-0.05 undefined	-0.05 undefined

	주당 매출	EBIT 당 주식	주당 이익
2017	0 AUD	-0.05 AUD	-0.05 AUD
2018	0 AUD	-0.09 AUD	-0.07 AUD
2019	0.01 AUD	-0.12 AUD	-0.12 AUD
2020	0.02 AUD	-0.14 AUD	-0.17 AUD
2021	0.03 AUD	-0.27 AUD	-0.29 AUD
2022	0.52 AUD	-0.29 AUD	-0.34 AUD
2023	1.55 AUD	0.05 AUD	0.02 AUD
2024e	2.32 AUD	0 AUD	0.18 AUD
2025e	3.04 AUD	0 AUD	0.25 AUD
2026e	4 AUD	0 AUD	0.58 AUD
2027e	3.84 AUD	0 AUD	0 AUD
2028e	4.79 AUD	0 AUD	0 AUD

	주식 수량
2017	127.99 백만 Aktien
2018	202.12 백만 Aktien
2019	233.44 백만 Aktien
2020	257.27 백만 Aktien
2021	282.21 백만 Aktien
2022	310.64 백만 Aktien
2023	323.71 백만 Aktien
2024e	323.71 백만 Aktien
2025e	323.71 백만 Aktien
2026e	323.71 백만 Aktien
2027e	323.71 백만 Aktien
2028e	323.71 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
0.13	0.09 (-30.1 %)	2024 Q2
0.08	0.06 (-25.43 %)	2023 Q4
0.03	-0.05 (-233.14 %)	2023 Q2
-0.05	-0.1 (-105.94 %)	2022 Q4
-0.11	-0.23 (-120 %)	2022 Q2
-0.08	-0.17 (-117.22 %)	2021 Q4
-0.1	-0.12 (-17.77 %)	2021 Q2
0	-0.1 (0 %)	2020 Q4

%-지분	이름	주식	변경
16.41248 %	Mitsubishi UFJ Financial Group Inc	54,929,795	54,929,795
3.33337 %	State Street Global Advisors Australia Ltd.	11,156,215	918,772
3.27091 %	Grand Decade Developments Ltd.	10,947,181	0
2.45205 %	The Vanguard Group, Inc.	8,206,611	45,029
2.22733 %	UV-Cap GmbH & Co KG	7,454,500	-70,500
1.83256 %	Norges Bank Investment Management (NBIM)	6,133,274	911,767
1.77163 %	Oncidium Foundation	5,929,331	-310,029
1.54203 %	Vanguard Investments Australia Ltd.	5,160,897	99,801
0.99027 %	BlackRock Institutional Trust Company, N.A.	3,314,268	13,653
0.98543 %	Lightpoint Medical Ltd	3,298,073	3,298,073
0.68421 %	State Street Global Advisors (US)	2,289,922	-2,020
0.59214 %	Yelwac Pty. Ltd.	1,981,804	-400,000
0.58066 %	Netwealth Investments Ltd.	1,943,357	-12,082
0.51791 %	Aglub Holdings Pty. Ltd.	1,733,342	1,733,342
0.49780 %	Sage Capital Pty Ltd.	1,666,045	162,572
0.42791 %	BetaShares Capital Ltd.	1,432,157	-122,330
0.39000 %	MLC Asset Management	1,305,276	-26,388
0.36759 %	AllianceBernstein L.P.	1,230,254	0
0.32979 %	Portland Investment Counsel Inc.	1,103,764	62,500
0.32153 %	RQI Investors	1,076,118	240,115
0.31565 %	Pendal Group Limited	1,056,433	102,874
0.24513 %	DFA Australia Ltd.	820,405	152,409
0.24053 %	Pengana Capital Group Limited	805,000	0
0.22724 %	American Century Investment Management, Inc.	760,536	740,044
0.21463 %	BlackRock Investment Management (Australia) Ltd.	718,323	14,337
0.21152 %	Charles Schwab Investment Management, Inc.	707,933	167,285
0.18198 %	Dimensional Fund Advisors, L.P.	609,069	7,479
0.17899 %	RBC Global Asset Management (Asia) Limited	599,035	599,035
0.16339 %	FIL Investment Management (Australia) Limited	546,849	0
0.15267 %	Polar Capital LLP	510,964	-116,822
0.15243 %	Handelsbanken Kapitalf¿rvaltning AB	510,155	16,199
0.11022 %	JPMorgan Asset Management U.K. Limited	368,898	368,898
0.09629 %	California Public Employees' Retirement System	322,273	17,433
0.09345 %	Bennelong Long Short Equity Management Pty Ltd	312,747	0
0.08880 %	Florida State Board of Administration	297,200	59,146
0.07799 %	California State Teachers Retirement System	261,034	17,027
0.07309 %	Hayward (C)	244,621	244,621
0.07152 %	Geode Capital Management, L.L.C.	239,379	-1,176
0.06557 %	MLC Investments Limited	219,463	54,211
0.06073 %	Bessemer Trust Company, N.A. (US)	203,245	190,675
0.06067 %	BlackRock Advisors (UK) Limited	203,058	2,054
0.05877 %	Nuveen LLC	196,709	0
0.05374 %	Scottish Widows Unit Trust Managers Ltd	179,853	2,744
0.05373 %	First Sentier Investors	179,811	-6,400
0.05023 %	Veritas Asset Management LLP	168,107	168,107
0.04090 %	Alpha Architect, LLC	136,891	136,891
0.04039 %	EntrepreneurShares LLC	135,186	0
0.03854 %	Evelyn Partners Investment Management LLP	129,000	-28,000
0.03734 %	UBS Fund Management (Switzerland) AG	124,976	5,489
0.03706 %	State Street Global Advisors Ireland Limited	124,021	480
0.03582 %	Fidelity International	119,872	2,365
0.03389 %	Federal Finance Gestion	113,411	0
0.03268 %	EAM Investors, LLC	109,375	109,375
0.02740 %	UBS Asset Management (UK) Ltd.	91,712	0
0.02576 %	Harbour Asset Management Limited	86,224	20,810
0.02533 %	Wellington Management Company, LLP	84,777	84,777
0.02394 %	WCM Investment Management	80,110	80,110
0.02356 %	Northern Trust Global Investments Limited	78,843	0
0.01943 %	BlackRock Asset Management Canada Limited	65,042	0
0.01861 %	Mercer Global Investments Management Ltd	62,276	0
0.01781 %	Z¿rcher Kantonalbank (Asset Management)	59,623	0
0.01719 %	Jupiter Asset Management Ltd.	57,548	57,548
0.01654 %	Nomura Asset Management U.S.A. Inc.	55,353	55,353
0.01511 %	KLP Fondsforvaltning AS	50,566	5,133
0.01503 %	Causeway Capital Management LLC	50,290	13,990
0.01427 %	Nordea Investment Management AB (Denmark)	47,745	47,745
0.01343 %	BlackRock Investment Management (UK) Ltd.	44,939	0
0.00959 %	Dimensional Fund Advisors, Ltd.	32,101	6,010
0.00883 %	Victory Capital Management Inc.	29,567	10,419
0.00853 %	Macquarie Investment Management Global Ltd.	28,558	0
0.00849 %	Operadora Valmex de Fondos de Inversión, S.A. de C.V.	28,403	0
0.00772 %	M.M.Warburg & CO (AG & Co.) KGaA	25,850	0
0.00739 %	Fideuram Asset Management (Ireland) dac	24,726	3,726
0.00707 %	Legal & General Investment Management Ltd.	23,657	0
0.00622 %	DWS Investment GmbH	20,829	187
0.00481 %	UBS Asset Management (Switzerland)	16,107	0
0.00424 %	Mackenzie Investments	14,193	-11,494
0.00395 %	Pictet Asset Management Ltd.	13,214	0
0.00373 %	Vanguard Global Advisers LLC	12,496	372
0.00304 %	Nomura Asset Management Singapore Ltd.	10,167	10,167
0.00300 %	Harris Associates L.P.	10,024	0
0.00256 %	TOBAM	8,554	3
0.00247 %	Lazard Asset Management, L.L.C.	8,282	8,282
0.00240 %	Axxion S.A.	8,020	1,642
0.00227 %	Origin Asset Management LLP	7,602	0
0.00213 %	Global X Management (AUS) Limited	7,141	528
0.00203 %	HSBC Global Asset Management (UK) Limited	6,800	0
0.00172 %	DWS Investments UK Limited	5,742	-914
0.00145 %	Invesco Capital Management LLC	4,848	0
0.00120 %	Northern Trust Investments, Inc.	4,018	0
0.00120 %	Dara Capital US, Inc.	4,009	0
0.00108 %	Milliman Financial Risk Management, LLC	3,606	0
0.00088 %	Connor, Clark & Lunn Investment Management Ltd.	2,955	-447
0.00085 %	Tredje AP Fonden	2,854	-99,433
0.00030 %	State Street Global Advisors (UK) Ltd.	1,018	0
0.00024 %	Rakuten Investment Management, Inc.	800	800
0.00007 %	Aegon Asset Management Ltd	219	4
0.00003 %	FIL Investment Management (Hong Kong) Limited	90	-31
0 %	Firetrail Investments Pty Limited	0	-232,544
0 %	Nelson (Mark)	0	-3,628,750

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
Eckert & Ziegler Strahlen	공급업체고객	0,81	0,62	0,79	0,79	0,34	0,77
Merck	공급업체고객	0,75	0,42	-0,03	0,64	0,66	0,91
Mauna Kea Technologies O	공급업체고객	0,68	0,33	0,09	0,60		-0,44
Grand Pharmaceutical Group	공급업체고객	0,66	0,52	0,51	0,70	0,10	-0,10
Heidelb Ph	공급업체고객	0,66	0,26	-0,68	-0,29	-0,27	0,34
Yantai Dongcheng Biochems A	공급업체고객	0,38	0,49	0,65	0,80	0,06	-0,61
Amgen	공급업체고객	0,34	0,57	-0,58	-0,55	-0,51	-0,51
HSBC Holdings	공급업체고객	0,23	0,47	0,56	-0,36	-0,15	0,61
Cardinal Health	공급업체고객	0,05	0,48	-0,59	-0,72	-0,62	-0,01
JPMorgan Chase	공급업체고객	-0,18	0,43	0,81	0,82	0,49	0,86

What values and corporate philosophy does Telix Pharmaceuticals represent?

Telix Pharmaceuticals Ltd represents a strong commitment to improving the diagnosis and treatment of cancer. With a focus on molecularly targeted radiation therapy, the company aims to develop innovative radiopharmaceuticals that can deliver more precise and effective cancer treatments. Telix Pharmaceuticals embraces a patient-centered approach, continually striving to enhance patient outcomes and improve quality of life. The company is dedicated to fostering collaborations, driving scientific advancements, and delivering transformative therapies to individuals battling cancer. Telix Pharmaceuticals Ltd stands as a beacon of innovation, aiming to revolutionize the field of cancer medicine with its cutting-edge technologies and unwavering dedication to making a difference.

In which countries and regions is Telix Pharmaceuticals primarily present?

Telix Pharmaceuticals Ltd primarily operates in several countries and regions, including Australia, the United States, Europe, and Japan.

What significant milestones has the company Telix Pharmaceuticals achieved?

Telix Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully completed its Phase III clinical trial for TLX591-CDx, a prostate cancer imaging agent. Additionally, Telix Pharmaceuticals received regulatory approval in the United States, Europe, and Canada for TLX591-CDx, allowing for its commercialization. Another notable achievement is the successful completion of a collaboration agreement with China Grand Pharma, expanding Telix's presence in the Chinese market. Furthermore, Telix Pharmaceuticals entered into a licensing agreement with ANMI SA, enhancing its product portfolio for molecular imaging. These achievements highlight Telix Pharmaceuticals' commitment to developing innovative solutions in the field of radiopharmaceuticals.

What is the history and background of the company Telix Pharmaceuticals?

Telix Pharmaceuticals Ltd is an innovative biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer diagnosis and treatment. Established in 2016, Telix has rapidly grown into a global player in the molecularly targeted radiation therapy field. The company has successfully acquired and developed a diverse portfolio of diagnostic and therapeutic products, leveraging its cutting-edge technology and strategic partnerships. Telix has made significant progress in clinical trials, regulatory approvals, and commercialization efforts, demonstrating its commitment to improving patient outcomes in oncology. With its dedicated team and robust pipeline, Telix Pharmaceuticals Ltd is poised to revolutionize cancer management through personalized and targeted radiopharmaceuticals.

Who are the main competitors of Telix Pharmaceuticals in the market?

The main competitors of Telix Pharmaceuticals Ltd in the market are other pharmaceutical companies operating in the same sector, focusing on molecularly targeted radiation (MTR) therapies and diagnostic imaging products for oncology. These competitors include established players such as Advanced Accelerator Applications SA (a Novartis company), Bayer AG, Curium Pharmaceuticals, and Progenics Pharmaceuticals. Telix Pharmaceuticals Ltd distinguishes itself through its innovative radiopharmaceutical solutions, strategic collaborations, and ongoing clinical trials.

In which industries is Telix Pharmaceuticals primarily active?

Telix Pharmaceuticals Ltd is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Telix Pharmaceuticals?

The business model of Telix Pharmaceuticals Ltd revolves around the development and commercialization of molecularly targeted radiation (MTR) products. As a leading biopharmaceutical company, Telix focuses on producing innovative diagnostic and therapeutic solutions for patients suffering from cancer. By utilizing its expertise in radiopharmaceuticals and molecular targeting, Telix aims to enhance the precision and efficacy of cancer diagnosis, imaging, and treatment. Through collaborations with various partners, Telix strives to bring advanced diagnostic imaging technologies and personalized treatment options to healthcare professionals and patients worldwide. Telix Pharmaceuticals Ltd plays a crucial role in improving patient outcomes and advancing the field of nuclear medicine.

Telix Pharmaceuticals 2024의 P/E 비율은 얼마입니까?

Telix Pharmaceuticals의 P/E 비율은 120.63입니다.

Telix Pharmaceuticals 2024의 KUV는 얼마입니까?

Telix Pharmaceuticals의 P/S 비율은 9.39입니다.

Telix Pharmaceuticals의 AlleAktien 품질 점수는 얼마인가요?

Telix Pharmaceuticals에 대한 AlleAktien 품질 점수는 3/10입니다.

Telix Pharmaceuticals 2024의 매출은 얼마인가요?

예상되는 Telix Pharmaceuticals 매출은 778.13 백만 AUD입니다.

Telix Pharmaceuticals 2024의 이익은 얼마인가요?

예상되는 Telix Pharmaceuticals 이익은 60.54 백만 AUD입니다.

Telix Pharmaceuticals은 무엇을 하나요?

Telix Pharmaceuticals Ltd is an Australian biotechnology company specializing in the development and commercialization of diagnostic technologies and therapeutic products for oncology.

Telix Pharmaceuticals 배당금은 얼마입니까?

Telix Pharmaceuticals은(는) 연간 번의 배당을 통해 0 AUD의 배당금을 지급합니다.

Telix Pharmaceuticals이 얼마나 자주 배당을 지급하나요?

Telix Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Telix Pharmaceuticals ISIN이 무엇입니까?

Telix Pharmaceuticals의 ISIN은 AU000000TLX2입니다.

Telix Pharmaceuticals WKN은 무엇인가요?

Telix Pharmaceuticals의 WKN은 A2H7JK입니다.

Telix Pharmaceuticals 티커는 무엇인가요?

Telix Pharmaceuticals의 티커는 TLX.AX입니다.

Telix Pharmaceuticals이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Telix Pharmaceuticals은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Telix Pharmaceuticals은(는) 0 AUD의 배당금을 지급할 것으로 예상됩니다.

Telix Pharmaceuticals의 배당 수익률은 얼마입니까?

Telix Pharmaceuticals의 현재 배당 수익률은 입니다.

Telix Pharmaceuticals의 배당금은 언제 지급되나요?

Telix Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Telix Pharmaceuticals의 배당금은 얼마나 안전한가요?

Telix Pharmaceuticals은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Telix Pharmaceuticals의 배당금은 얼마입니까?

향후 12개월 동안 0 AUD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Telix Pharmaceuticals이(가) 속해 있는 섹터는 어디인가요?

Telix Pharmaceuticals은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Telix Pharmaceuticals의 마지막 배당금을 0 AUD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Telix Pharmaceuticals의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Telix Pharmaceuticals의 2023년도 배당금은 얼마였습니까?

2023년에 Telix Pharmaceuticals는 0 AUD를 배당금으로 지급했습니다.

Telix Pharmaceuticals는 어떤 화폐로 배당금을 지급하나요?

Telix Pharmaceuticals의 배당금은 AUD에 지급됩니다.

Scope 1 - 직접 방출
스코프 2 - 구매한 에너지로부터의 간접적인 배출
Scope 3 - 가치 창출 체인 내의 간접 배출
총 CO₂ 배출량
CO₂ 감소 전략
석탄 에너지
원자력
동물 실험
펠츠 & 레더
살충제
팜 오일
담배
유전자 변형 생물체
기후 개념
지속 가능한 임업
재활용 규정
환경 친화적인 포장
위험물질
연료 소비량과 효율성
물 사용량 및 효율성

여성 직원 비율	49
관리 직위에서의 여성 비율
아시아 직원 비율
아시아 경영진 비율
히스패닉/라티노 직원 비율
히스패닉/라티노 관리 부문 지분
흑인 직원 비율
블랙 매니지먼트 지분
흰색 종업원의 비율
화이트 매니지먼트 지분
성인 콘텐츠
알코올
무기
총기
도박
군사 계약
인권 개념
개인정보 보호 정책
작업 및 건강 보호
카톨릭

환경 보고
이해관계자 참여
콜백 정책
카르텔법

증권거래소	Telix Pharmaceuticals 티커
ASX	TLX.AX
PNK	TLPPF

Telix Pharmaceuticals 티커	Telix Pharmaceuticals FIGI
TLX:AU	BBG00HZHXWM5
TLX:AT	BBG00HZHXWN4
TLX:AH	BBG00HZHXWS9
T3X:TH	BBG00J9YR656
TLX2EUR:X2	BBG00JB5XWC4
TLX2EUR:XB	BBG00JB5XWD3
TLX2EUR:XH	BBG00JB5XWG0
TLX2EUR:XF	BBG00JB5XWJ7
TLX2EUR:XE	BBG00JB5XWL4
TLX2EUR:XJ	BBG00JB5XWM3
TLX2EUR:XL	BBG00JB5XWN2
TLX2EUR:XG	BBG00JB5XWP0
TLX2EUR:XO	BBG00JB5XWQ9
TLX2EUR:XS	BBG00JB5XWV3
TLX2EUR:XA	BBG00JB5XWX1
TLX2EUR:E1	BBG00JB5XWY0
TLX2EUR:XT	BBG00JB5XWZ9
TLX2EUR:XW	BBG00JB5XX05
TLX2EUR:XU	BBG00JB5XX14
TLX2EUR:XV	BBG00JB5XX23
TLX2EUR:XM	BBG00JB5XX32
TLX2EUR:EU	BBG00JB5XX69
TLX2EUR:XX	BBG00JN8P604
TLPPF:US	BBG00LJTBT58
TLPPF:PQ	BBG00LJTBTL0
TLPPF:UV	BBG00LJTBTM9
TLX2AUD:XH	BBG00QFSBKZ9
TLX2AUD:XF	BBG00QFSBL14
TLX2AUD:XE	BBG00QFSBL32
TLX2AUD:XL	BBG00QFSBL50
TLX2AUD:XG	BBG00QFSBL69
TLX2AUD:XO	BBG00QFSBL78
TLX2AUD:XA	BBG00QFSBLC2
TLX2AUD:XT	BBG00QFSBLF9
TLX2AUD:XW	BBG00QFSBLG8
TLX2AUD:XU	BBG00QFSBLH7
TLX2AUD:XV	BBG00QFSBLK3
TLX2AUD:XM	BBG00QFSBLL2
TLX2AUD:EU	BBG00QFSBLS5
T3X:GR	BBG00YG2LCL0
T3X:GM	BBG00YG2LCR4
T3X:GB	BBG00YG2LCS3
TLX2USD:X2	BBG010C6R0N6
TLX2USD:XH	BBG010C6R0Z3
TLX2USD:XF	BBG010C6R181
TLX2USD:XE	BBG010C6R1J9
TLX2USD:XL	BBG010C6R1V5
TLX2USD:XG	BBG010C6R1Z1
TLX2USD:XO	BBG010C6R243
TLX2USD:XA	BBG010C6R2Q9
TLX2USD:E1	BBG010C6R2V3
TLX2USD:XT	BBG010C6R305
TLX2USD:XW	BBG010C6R341
TLX2USD:XU	BBG010C6R396
TLX2USD:XV	BBG010C6R3L2
TLX2USD:XM	BBG010C6R3Q7
TLX2USD:XQ	BBG010C6R3W0
TLX2USD:XX	BBG010C6R412
TLX2USD:XZ	BBG010C6R467
TLX2USD:X1	BBG010C6R4J3
TLX2USD:EU	BBG010C6R9V8

한 눈에 저평가된 주식을 인식하세요

가격

가격

티커TLX.AX

ISINAU000000TLX2

WKNA2H7JK

Telix Pharmaceuticals 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Telix Pharmaceuticals 주가 이력

Telix Pharmaceuticals 주식 매출, EBIT, 이익 AU000000TLX2 · A2H7JK

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Telix Pharmaceuticals 매출, 이익 및 EBIT 역사

Telix Pharmaceuticals 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Telix Pharmaceuticals 주식 마진 AU000000TLX2 · A2H7JK

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Telix Pharmaceuticals 마진 역사

Telix Pharmaceuticals 주식 매출, EBIT, 주당 순이익 AU000000TLX2 · A2H7JK

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Telix Pharmaceuticals 매출, 이익 및 EBIT 주당 역사

Telix Pharmaceuticals 주식 및 주식 분석

한눈에 과소평가된 주식을 인식하세요.

Telix Pharmaceuticals Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Telix Pharmaceuticals 역사적인 P/E, EBIT 및 P/S에 따른 평가

한눈에 과소평가된 주식을 인식하세요.

Telix Pharmaceuticals 주식 수량 AU000000TLX2 · A2H7JK

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

한눈에 과소평가된 주식을 인식하세요.

Telix Pharmaceuticals 수익 예상

Telix Pharmaceuticals 수익 놀라움

Eulerpool ESG Scorecard© Telix Pharmaceuticals 주식을 위해

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

티커
TLX.AX

ISIN
AU000000TLX2

WKN
A2H7JK